Johnson & Johnson Surpasses Earnings Forecast with Robust Drug Sales
In the first quarter, Johnson & Johnson exceeded Wall Street forecasts due to high demand for cancer drug Darzalex and psoriasis treatment Tremfya. Despite a significant Stelara sales decline, quarterly revenues rose nearly 10% to $24.1 billion. The company anticipates a growing impact from new products throughout the year.
Johnson & Johnson outperformed expectations in its first-quarter earnings, attributed primarily to strong sales of its cancer drug Darzalex and psoriasis treatment Tremfya. This came as a surprise against the backdrop of a noticeable decline in revenue from its blockbuster Stelara, which faced significant competition after losing patent protection.
The pharmaceutical giant reported a 10% revenue increase year-over-year, reaching $24.1 billion, surpassing analysts' predicted $23.6 billion. Despite Stelara sales dropping by 60% to $656 million, Tremfya and newly launched Icotyde drugs bolstered the company's standings, promising future growth.
Company officials anticipate a growing impact from newly launched products as the year progresses. With advances in its medical technology sector and strategic drug pricing agreements, Johnson & Johnson has adjusted its full-year forecasts, hinting at continued expansion and adaption to competitive market dynamics.
Google News